The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Interventions for valvular disease and heart failure
Transapical transcatheter mitral valve implantation in patients with prior aortic valve replacement: a feasibility report
Maurizio Taramasso1, MD; Paul Sorajja2, MD; Gry Dahle3, MD; Nicolas Dumonteil4, MD; Ulrich Schäfer5, MD; Thomas Modine6, MD; Pavel Overtchouk6, MD; Augustin Coisne6, MD; Georg Nickenig7, MD; Vasilis Babaliaros8, MD; Ahmed A. Khattab1,9,10, MD; Sebastian Ludwig5, MD; Lenard Conradi5, MD
1. University Hospital of Zurich, University of Zurich, Zurich, Switzerland; 2. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, USA; 3. Department of Cardiothoracic Surgery, Oslo University, Oslo, Norway; 4. Clinique Pasteur, Toulouse, France; 5. University Heart Center, Hamburg, Germany; 6. Cardiovascular Surgery Department, Cœur Poumon CHU de Lille, Lille, France; 7. Heart Center Bonn, University Hospital, Bonn, Germany; 8. Emory Structural Heart and Valve Center, Atlanta, GA, USA; 9. Cardiance Clinic, Pfäffikon, Switzerland; 10. University of Bern, Bern, Switzerland
Introduction
Transcatheter mitral valve implantation (TMVI) has recently emerged as a treatment option for selected high-risk patients with symptomatic mitral regurgitation (MR).
Although the feasibility of TMVI in patients with previous aortic valve (AV) prostheses has been reported1, the interaction between a TMVI and an AV prosthesis has not previously been well characterised. In particular, the risk of left ventricular outflow tract (LVOT) obstruction after TMVI may be higher in patients with a pre-existing aortic valve prosthesis, due to the presence of concomitant LV hypertrophy. Moreover, the frame of the aortic prosthesis can extend into the LVOT, and ...
Transcatheter mitral valve implantation (TMVI) has recently emerged as a treatment option for selected high-risk patients with symptomatic mitral regurgitation (MR).
Although the feasibility of TMVI in patients with previous aortic valve (AV) prostheses has been reported1, the interaction between a TMVI and an AV prosthesis has not previously been well characterised. In particular, the risk of left ventricular outflow tract (LVOT) obstruction after TMVI may be higher in patients with a pre-existing aortic valve prosthesis, due to the presence of concomitant LV hypertrophy. Moreover, the frame of the aortic prosthesis can extend into the LVOT, and ...
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Interventions for valvular diseaseInterventions for heart failureMitral valve replacement and repairChronic heart failure
Read next article
Outcomes of directional atherectomy for common femoral artery disease
Latest news
AHEAD OF PRINT
Robotic-assisted CABG: clinical outcomes
FREE ARTICLE - Aleksander Dokollari et al
November 23, 2023
PCR London Valves 2023
November 16, 2023
NEW ISSUE
PCR London Valves special edition. State-of-the-art on TMVI; the timing of TMVI; direct wire pacing for TMVR; predicting patient-prosthesis mismatch following TAVI and more
November 17, 2023
AHEAD OF PRINT
Pathophysiological CAD patterns predict outcomes post-PCI
FREE ARTICLE - Nozomi Kotoku et al
November 14, 2023
AHEAD OF PRINT
Extra-mitral valve cardiac involvement in MR
FREE ARTICLE - Antonio Popolo Rubbio et al
November 9, 2023
AHEAD OF PRINT
Cardiac damage classification in each AS subtype
FREE ARTICLE - Masaaki Nakase et al
November 6, 2023
AHEAD OF PRINT
CAPTIS embolic protection during TAVR
FREE ARTICLE - Haim D. Danenberg et al
November 2, 2023